What Is Enclomiphene and How Does It Work?

What is enclomiphene? Enclomiphene is the trans-isomer of clomiphene citrate and a selective estrogen receptor modulator (SERM) studied in men with secondary hypogonadism (low testosterone driven by the brain rather than the testes). Instead of supplying testosterone from the outside, it nudges the body to make more of its own. Importantly, enclomiphene is not FDA-approved for any use; in the United States it is available only as a compounded, prescription-only medication used off-label in men, and the FDA has not evaluated compounded enclomiphene for safety, effectiveness, or quality. This article is educational information, not medical advice.

What exactly is enclomiphene?

Clomiphene citrate is a mixture of two stereoisomers. Enclomiphene is the more anti-estrogenic trans-isomer, while zuclomiphene is the more estrogenic, longer-lasting cis-isomer. Isolating the enclomiphene portion is the idea behind using it on its own in men, as described in the 2026 BSSM position statement.

One distinction matters for compliance: clomiphene (the racemic parent compound) is FDA-approved only for female ovulatory dysfunction. Enclomiphene as a single agent has never been FDA-approved, and approval of the parent drug for women does not imply approval of enclomiphene for men.

How does enclomiphene work in the body?

Testosterone production is governed by a feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis. Estrogen normally signals the brain to slow down. Enclomiphene competes with estrogen at receptors in the hypothalamus and pituitary, blunting that negative feedback. The brain responds by releasing more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the testes’ own testosterone production and support sperm development, as outlined in a PubMed review of enclomiphene for secondary hypogonadism.

Because it acts upstream rather than replacing testosterone, enclomiphene tends to keep the natural signaling chain intact. It is relatively short-acting compared with the long-lasting zuclomiphene isomer. If you are weighing this against injections or gels, our explainer on enclomiphene vs. TRT goes deeper on the trade-offs.

How is enclomiphene different from testosterone therapy?

The core differentiator is direction. Standard testosterone replacement therapy (TRT) supplies exogenous androgen, which suppresses the brain’s LH and FSH signals and tends to reduce sperm production. Enclomiphene does the reverse: it raises LH and FSH and tends to preserve spermatogenesis. For context on whether low testosterone may be relevant to you, see the signs you may need hormone replacement therapy.

Feature	Enclomiphene (compounded, not FDA-approved)	Testosterone therapy (TRT)
Mechanism	Upstream SERM; blocks estrogen feedback in the brain	Supplies testosterone directly
Effect on LH/FSH	Raises them	Suppresses them
Sperm production	Tends to be preserved in trials	Tends to be suppressed
Form	Oral (compounded)	Injection, gel, pellet, patch
Regulatory status	Not FDA-approved; compounded; off-label in men	FDA-approved; DEA Schedule III

Testosterone itself is a DEA Schedule III controlled substance requiring a prescription and monitoring. In 2025 the FDA issued class-wide labeling changes for testosterone products, adding a warning about increased blood pressure and removing the prior cardiovascular boxed-warning language based on the TRAVERSE trial. Our TRT dosage guide covers that pathway in more detail.

What does the research actually show?

In a randomized phase II trial (ZA-203) of 124 men with secondary hypogonadism, comparing enclomiphene citrate (12.5 mg or 25 mg daily) with 1% topical testosterone gel and placebo over 3 months, enclomiphene raised morning total testosterone, estradiol, LH, and FSH to levels similar to the gel while preserving sperm production — the gel group showed lower sperm parameters. That trial is Wiehle et al., Fertility and Sterility 2014.

A separate 2025 systematic review and meta-analysis of 10 randomized controlled trials (819 men with hypogonadism) found that SERM therapy (clomiphene or enclomiphene) increased total testosterone by about +274 ng/dL (95% CI 191.87–355.66), LH by about +4.66 IU/L, and FSH by about +4.59 IU/L versus placebo, with sperm concentration roughly 70 million/mL higher than testosterone gel. These are pooled averages in men, not guarantees for any individual, and follow-up across the included trials ran only 2–30 weeks.

Expert guidance reflects this caution. The 2026 BSSM position statement calls enclomiphene a promising oral option for men with secondary hypogonadism who wish to preserve fertility, but stresses that it is unlicensed (not FDA- or EMA-approved), has limited long-term safety and efficacy data, and should be limited to specialist or research settings with counseling. If you want the granular tolerability picture, read up on enclomiphene side effects.

Is enclomiphene FDA-approved or legal to use?

No medication called enclomiphene is FDA-approved. The US Department of Defense’s Operation Supplement Safety confirms that enclomiphene has not been approved by the FDA for any use and is a drug, not a dietary supplement.

Its development history reinforces this. Repros Therapeutics’ branded enclomiphene, Androxal, received an FDA Complete Response Letter in 2015; the FDA said the Phase 3 design was no longer adequate to demonstrate clinical benefit and asked for additional studies. The product was never approved, and development was not pursued further.

On the compounding side, the picture has two true-at-once facts worth understanding. On June 8, 2022 the FDA’s Pharmacy Compounding Advisory Committee voted against adding enclomiphene citrate to the final 503A bulks list. Yet as of the FDA’s nominated-substances list updated May 14, 2026, enclomiphene citrate remains Category 1 (“under evaluation”), meaning it may continue to be compounded under interim enforcement discretion pending a final FDA decision. The advisory vote did not place it on the final list, but the FDA has not finalized removal — so it stays in the interim bucket. Neither statement means enclomiphene is approved or that any vote endorsed it.

Who might consider enclomiphene?

In the studied context, enclomiphene is framed for men with secondary hypogonadism — particularly those who want to maintain fertility while addressing low testosterone. It is not studied or framed for women, and it is not a supplement, a fitness shortcut, or an anti-aging agent. Whether it is appropriate for you is a clinical judgment that depends on your labs, history, and goals, and only a licensed provider can make it. Some men also consider other, unrelated products such as NAD+ injections or PT-141 for separate concerns; like enclomiphene, the compounded options are not FDA-approved and carry their own disclosures.

Frequently asked questions

Is enclomiphene the same as clomid?

Not exactly. Clomid (clomiphene citrate) is a mixture of two isomers; enclomiphene is just the trans-isomer of that mixture. Clomiphene is FDA-approved only for female ovulatory dysfunction, whereas single-agent enclomiphene is not FDA-approved and is used off-label in men as a compounded drug.

Does enclomiphene increase testosterone?

In men with secondary hypogonadism, trials report increases in total testosterone, LH, and FSH. A 2025 meta-analysis of 10 RCTs (819 men) found SERM therapy raised total testosterone by about +274 ng/dL versus placebo. These are study averages, not guarantees, and individual results vary.

Does enclomiphene preserve fertility?

Because it works upstream and raises LH and FSH, enclomiphene tends to preserve sperm production in trials, unlike testosterone gel, which suppressed it in the same studies. This is a relative advantage seen versus TRT, not a promise of fertility for any person.

Is enclomiphene FDA-approved?

No. Enclomiphene is not FDA-approved for any use. Branded enclomiphene (Androxal) received an FDA Complete Response Letter in 2015 and was never approved. In the US it is available only as a compounded, prescription-only medication, and the FDA has not evaluated compounded enclomiphene for safety, effectiveness, or quality.

How long does enclomiphene take to work?

Enclomiphene is relatively short-acting and clears the bloodstream faster than the long-lasting zuclomiphene isomer. In the phase II trial, men dosed daily showed testosterone increases over the 3-month treatment period; an earlier short-term study reported rises within about two weeks. Real-world timelines are provider-determined and depend on your labs and response; individual results vary.

Is enclomiphene safe long-term?

Long-term safety data are limited. Trials to date are small and short (2–30 weeks), and the 2026 BSSM statement emphasizes its unlicensed status and limited long-term evidence, recommending use only in specialist or research settings with counseling.